TickerFacts.

Ginkgo Bioworks Holdings, Inc. (DNA): Revenue

Annual figures by period end, from SEC filings.

$170.16M
Year ended 2025-12-31
-29.1%
3-year compound annual growth
+17.3%
5-year compound annual growth
$477.71M2019-12-31: $54.18M2020-12-31: $76.66M2021-12-31: $313.84M2022-12-31: $477.71M2023-12-31: $251.46M2024-12-31: $227.04M2025-12-31: $170.16M$170.16M
2019-12-31 Revenue (USD) 2025-12-31
Period endedRevenueChange YoYSource filing
2025-12-31$170.16M-25.1%2026-02-26, From 2025-01-01
2024-12-31$227.04M-9.7%2026-02-26, From 2024-01-01
2023-12-31$251.46M-47.4%2026-02-26, From 2023-01-01
2022-12-31$477.71M+52.2%2025-02-25, From 2022-01-01
2021-12-31$313.84M+309.4%2024-02-29, From 2021-01-01
2020-12-31$76.66M+41.5%2023-03-13, From 2020-01-01
2019-12-31$54.18Mn/a2022-03-29, From 2019-01-01

Revenue at similar companies

Companies with the same SEC industry code (Biological Products, (No Diagnostic Substances)), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedRevenueChange YoY
Ginkgo Bioworks Holdings, Inc. (DNA)2025-12-31$170.16M-25.1%
REGENXBIO Inc. (RGNX)2025-12-31$170.44M+104.5%
Adaptimmune Therapeutics PLC (ADAPY)2024-12-31$178.03M+195.3%
Beam Therapeutics Inc. (BEAM)2025-12-31$139.74M+120.0%
Monte Rosa Therapeutics, Inc. (GLUE)2025-12-31$123.67M+63.5%
Vaxart, Inc. (VXRT)2025-12-31$237.26M+726.7%
Atara Biotherapeutics, Inc. (ATRA)2025-12-31$120.77M-6.3%
Agenus Inc (AGEN)2025-12-31$114.20M+10.4%
ImmunityBio, Inc. (IBRX)2025-12-31$113.29M+668.3%

Compare DNA, RGNX, ADAPY, BEAM side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗